What's in a (tumor) cavity?
作者信息
McKay Michael J
机构信息
School of Cancer Medicine, La Trobe University, Olivia Newton-John Cancer Research Institute at Austin Campus, Heidelberg, Australia.
出版信息
Transl Lung Cancer Res. 2020 Feb;9(1):8-9. doi: 10.21037/tlcr.2019.10.01.
Abstract
摘要
相似文献
1
What's in a (tumor) cavity?
Transl Lung Cancer Res. 2020 Feb;9(1):8-9. doi: 10.21037/tlcr.2019.10.01.
2
A commentary on the evolution of NIH: what's in, what's out, what's hot, what's not.
Integr Physiol Behav Sci. 1998 Apr-Jun;33(2):115-7. doi: 10.1007/BF02688652.
3
Cardiovascular product update and evaluation. What's hot, what's not, what's in, what's out.
J Interv Cardiol. 1994 Apr;7(2):203-4. doi: 10.1111/j.1540-8183.1994.tb00905.x.
4
Cardiovascular product update and evaluation. What's hot, what's not, what's in, what's out.
J Interv Cardiol. 1992 Mar;5(1):67-8. doi: 10.1111/j.1540-8183.1992.tb00827.x.
5
Small animal dermatopathology: 'what's old, what's new, what's borrowed, what's useful'.
Semin Vet Med Surg Small Anim. 1987 Aug;2(3):162-5.
6
The Editor's Workshop: Pediatric and adolescent gynecology: What's the issue? What's the answer? What's the big picture? What's the national perspective?
J Pediatr Adolesc Gynecol. 2009 Aug;22(4):195-6. doi: 10.1016/j.jpag.2009.06.001.
7
Update on health care in Canada: what's right, what's wrong, what's left.
J Public Health Policy. 1998;19(3):267-88.
8
Differences in the What's My M3? test between pre- and postmenopausal women.
Prz Menopauzalny. 2017 Sep;16(3):104-106. doi: 10.5114/pm.2017.70588. Epub 2017 Oct 12.
9
Dermatologic therapy--1960. What's new? and what's true of what's new?
Acta Derm Venereol. 1961;41:187-93.
10
What's new and what's true of what's new in dermatology.
Calif Med. 1955 Jul;83(1):1-5.
本文引用的文献
1
Influence and mechanism of lung cavitation development on antiangiogenic therapy.
Transl Lung Cancer Res. 2019 Aug;8(4):500-512. doi: 10.21037/tlcr.2019.07.01.
2
Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.
Thorac Cancer. 2014 Sep;5(5):438-46. doi: 10.1111/1759-7714.12115. Epub 2014 Aug 25.
3
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.
Cancer Imaging. 2012 Jun 29;12(1):225-35. doi: 10.1102/1470-7330.2012.0027.
4
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
Cancer Sci. 2011 Jul;102(7):1374-80. doi: 10.1111/j.1349-7006.2011.01939.x. Epub 2011 May 9.
5
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
J Clin Oncol. 2009 Jan 20;27(3):404-10. doi: 10.1200/JCO.2008.16.2545. Epub 2008 Dec 1.
6
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.
J Thorac Oncol. 2008 Apr;3(4):351-7. doi: 10.1097/JTO.0b013e318168c7e9.
7
Primary pulmonary cavitating carcinomas.
Thorax. 1973 May;28(3):354-66. doi: 10.1136/thx.28.3.354.
Zotero 插件